pSivida gets some relief with $10.75 million financing
This article was originally published in Scrip
Executive Summary
pSivida, a US company developing sustained-release drug delivery products for eye diseases, has agreed a $10.75 million financing with institutional investors that will provide some breathing space following the company's recent regulatory setback with its lead development product, Iluvien (fluocinolone acetonide intravitreal insert).